<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:department>Pharmacology</gtr:department><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6CC7D151-7E06-4736-BA0E-6CA1CE0CADE5"><gtr:id>6CC7D151-7E06-4736-BA0E-6CA1CE0CADE5</gtr:id><gtr:name>Novartis Pharmaceuticals UK Ltd</gtr:name><gtr:address><gtr:line1>Frimley Business Park</gtr:line1><gtr:line2>GB-Frimley</gtr:line2><gtr:line4>Camberley</gtr:line4><gtr:line5>Surrey</gtr:line5><gtr:postCode>GU16 7SR</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>PROJECT_PARTNER</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/8E8A7ED7-B434-4261-A5D5-86C0FD5BD714"><gtr:id>8E8A7ED7-B434-4261-A5D5-86C0FD5BD714</gtr:id><gtr:firstName>Colin</gtr:firstName><gtr:otherNames>William</gtr:otherNames><gtr:surname>Taylor</gtr:surname><gtr:roles><gtr:role><gtr:name>TRAINING_GRANT_HOLDER</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.ukri.org:80/person/F9BBB3EC-68AF-4407-91BA-4E1F649CE113"><gtr:id>F9BBB3EC-68AF-4407-91BA-4E1F649CE113</gtr:id><gtr:firstName>Mark</gtr:firstName><gtr:surname>Dowling</gtr:surname><gtr:roles><gtr:role><gtr:name>RESEARCHER_COI</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FI015574%2F1"><gtr:id>0E3DECFA-9848-4789-B05B-412B360E9A03</gtr:id><gtr:title>Interactions between cyclic AMP and calcium signalling pathways in airway smooth muscle cells.</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Training Grant</gtr:grantCategory><gtr:grantReference>BB/I015574/1</gtr:grantReference><gtr:abstractText>Ca2+ and cAMP are delivered to cells as spatially organised signals and reciprocal interactions between them are widespread. In bronchial airways, for example, Ca2+ is the primary control of contraction, via activation of myosin light chain kinase, while receptors that evoke cAMP formation cause relaxation. Both pathways are targets of drugs used to treat asthma and chronic obstructive pulmonary disease (COPD), with agonists of beta2-receptors and antagonists of M3 muscarinic receptors in widespread clinical use. In combination therapy, these drugs act at least additively and perhaps synergistically,but the nature of the interactions is undefined. In human bronchial airway smooth muscle cells (BASMC), cAMP attenuates Ca2+ signals and the Ca2+-sensitivity of the contractile apparatus; and Ca2+ attenuates cAMP signalling. The mechanisms underlying these physiologically and clinically important interactions are unresolved. Hitherto interactions between M3 and beta2 receptors have relied on heterologous expression in cell lines, but they need to be explored in native human tissues that retain an appropriate cohort of signalling proteins. Novartis is developing combination therapies for COPD, but there is presently no human pre-clinical model for assessment of their efficacy, and limited knowledge from which to identify possible drug targets downstream of receptors. Human bronchial airway smooth muscle cells (BASMC) in culture largely retain their native phenotype for up to 10 passages, but transfection is required to maintain normal levels of M3 receptors. These cells currently provide the best model for signalling analyses in BASMC. Our aims are to identify sites of interaction between cAMP and Ca2+ in human BASMC stimulated with agonists of beta2 and M3 receptors.</gtr:abstractText><gtr:fund><gtr:end>2015-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2011-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>91932</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">BB/I015574/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>